Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17831407 | 0.76 | KMT2A (0.51) | GAAKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL2477935 | 0.76 | NPC1 (0.57) | ALDH1A1NPC1RAB9AMGLLKMT2A | |
| SCHEMBL537486 | 0.75 | KMT2A (0.54) | GAAALDH1A1MGLLKMT2AMAPT | |
| SCHEMBL132757 | 0.75 | MEN1 (0.65) | GAAALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL29656505 | 0.75 | MGLL (0.46) | GAAKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL24218417 | 0.73 | ALDH1A1 (0.64) | GAAKDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL537548 | 0.73 | CNR2 (0.49) | GAAKDM4EALDH1A1RAB9AMGLL | |
| SCHEMBL3080087 | 0.72 | RAB9A (0.67) | GAAKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL3573967 | 0.72 | MAPT (0.66) | GAAALDH1A1NPC1RAB9AMGLL | |
| SCHEMBL28542399 | 0.72 | KDM4E (0.70) | GAAKDM4EALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414366-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | Novartis AG (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2012-01-12 | — | — | US | disclosed |
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2012-01-12 | — | — | US | disclosed |
| WO-2010112520-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | GAA 1280/4885KDM4E 1529/4885ALDH1A1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.